Company intelligence / Profile preview

Migration Biotherapeutics

Cardiff, Wales, United Kingdomlinkedin.com ↗

Ownership: Private
Development stage: Other

Overview

Migration Biotherapeutics is developing a novel device/biomaterial that emits signals stronger than healthy brain tissue to attract migrating cancer cells—primarily targeting glioblastoma. The technology is currently being optimized in preclinical settings with plans to map out clinical trials. No clinical results have been reported yet.

Therapeutic areas: OncologyOther
Modalities: DeviceBiomaterial-based therapy
Industry: Therapeutic Medical Devices

Partnerships

King's College London/Kings20 Accelerator program support

Beyond the preview

Go deeper on Migration Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Migration Biotherapeutics.

Explore the full profile